Ion beam therapy with concurrent chemotherapy using Gemcitabine for unresectable pancreatic cancer, Phase I/II study
Not Applicable
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000002173
- Lead Sponsor
- Department of Radiology, Hyogo Ion Beam Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
distal metastases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method QOL survival time
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergy between ion beam therapy and Gemcitabine in pancreatic cancer?
How does ion beam therapy with Gemcitabine compare to standard-of-care FOLFIRINOX in unresectable pancreatic cancer outcomes?
Which biomarkers correlate with response to ion beam-Gemcitabine combination in Hyogo Ion Beam Medical Center's Phase I/II trial?
What are the unique adverse events associated with carbon ion beam therapy and Gemcitabine in pancreatic cancer patients?
Are there alternative nucleoside analogs or targeted therapies being evaluated with ion beam therapy for KRAS-mutant pancreatic cancer?